Further upside potential for ResMed: RBS Morgans

RBS Morgans upgrades ResMed, taking into account greater benefits from Australian dollar tailwinds and skilled management.

ResMed (RMD) shares have more room for gains despite their recent run-up over the past month as the company's earnings strengthen and the Australian dollar provides greater tailwinds, according to RBS Morgans.

The broker upgraded the medical device maker's stock to "outperform" from "neutral", seeing a nearly 10% upside with a target price of $5.97.


SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles